HHM Global | B2B Online Platform & Magazine http://www.hhmglobal.com Hospital & Healthcare Management is a leading B2B Magazine & an Online Platform featuring global news, views, exhibitions & updates of hospital management industry. Wed, 21 Nov 2018 07:10:27 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.8 Intermountain Healthcare Supply Chain Reaches Master Level Ranking http://www.hhmglobal.com/knowledge-bank/news/intermountain-healthcare-supply-chain-reaches-master-level-ranking Tue, 20 Nov 2018 09:20:40 +0000 http://www.hhmglobal.com/uncategorized/intermountain-healthcare-supply-chain-reaches-master-level-ranking Annual Gartner Healthcare Supply Chain Top 25 list recognizes Intermountain Healthcare for initiatives to provide highest quality products and services at the lowest possible cost.

Intermountain Healthcare has reached a “Masters” designation in the annual Gartner Healthcare Supply Chain Top 25 list. The Healthcare Supply Chain Top 25 ranking and designation, recognizes manufacturers, providers, distributors and retailers from across healthcare that demonstrate leadership in improving human life at sustainable costs. After being ranked in the top five over the past seven years, Intermountain is recognized in Gartner’s new Master classification, an additional dimension of achievement. Gartner is a national business consulting company who has issued the ranking the past ten years.

Intermountain earned the Master level based on sustained supply chain performance over a period of time. Intermountain was ranked #1 on the Gartner list in 2016 and 2017 and #3 the two prior years. Intermountain’s strong bond rating, its supply chain organization’s initiatives to improve value and lower healthcare costs, the health system’s comprehensive approach to serve the patient, and innovative problem solving are among the factors to achieve the newly created title.

“Our supply chain team does an outstanding job to ensure we’re using the highest quality products and services at the lowest possible cost,” said Marc Harrison, MD, president and CEO of Intermountain Healthcare. “This team continually raises the bar in quality and affordability and demonstrates—year upon year—their commitment to making a difference for those we serve. We are honored to be on this prestigious list as a Master.”

John Wright, vice president of Supply Chain and Support Services for Intermountain, adds, “This is a humbling experience to now be ranked as a Master and a designation which I’m very appreciative. Intermountain Supply Chain leaders before me staged us for this honor long ago and I’m proud to have led us the past year to continue our work forward. Recognition of this type validates our passion and conviction within the supply chain to make a difference for our patients. I know that when we move initiatives forward, we do so with the dedication and commitment to improve value.”

Geisinger Launches Surgical Redesign Program to Reduce Opioid Use and Improve Patient Experience http://www.hhmglobal.com/industry-updates/press-releases/geisinger-launches-surgical-redesign-program-to-reduce-opioid-use-and-improve-patient-experience Tue, 20 Nov 2018 09:05:55 +0000 http://www.hhmglobal.com/uncategorized/geisinger-launches-surgical-redesign-program-to-reduce-opioid-use-and-improve-patient-experience Geisinger announced the launch of ProvenRecovery, a surgical redesign program aimed at expediting healing, improving pain management and reducing opioid use. The program will be implemented across 42 surgical procedures impacting approximately 15,000 surgery cases annually, with the goal of reaching 100 surgical specialties by the end of 2019.

ProvenRecovery combines the best practices of Geisinger’s ProvenCare® program in cardiac, bariatric, spine and joint surgical care, along with industry best practices in optimizing patients for elective surgeries. The ProvenRecovery pilot, which began in June 2017, has driven an 18 percent decrease in opioid usage across the organization. During the pilot, neurosurgery and colorectal surgery patients saw their hospital stays cut in half. Earlier discharges accounted for an average savings of $4,556 per case for colorectal surgery patients.

“In my 35 years in surgery, this is the innovation with the greatest potential to improve the patient experience, save lives, reduce complications and be less disruptive to patients,” said Neil Martin, MD, Geisinger’s chief quality officer and chair of Geisinger’s neuroscience institute. “With ProvenRecovery, we are empowering patients to be healthier before surgery, leading to fewer surgical complications and patients returning to their lives sooner.”

ProvenRecovery focuses on three key measures to empower patients be healthier before and after surgery:

Proper nutrition – During a pre-surgery consultation, patients receive a kit, including care instructions, mobility instructions and immunonutrition drinks. Unlike traditional fasting immediately preceding surgery, the fortified drinks are designed to get patients to a proper nutrition level before surgery to help reduce infection, accelerate healing after surgery and account for nutrition gaps in the average American diet.

Appropriate pain management – Surgery through this approach is opioid avoiding, and in many cases opioid free. During surgery, a patient’s pain is controlled by specifically targeting the surgical area. Known as multi-modal pain management, this technique allows for effective pain control of just one area. A combination of non-opioid medications is used, depending on the surgery, such as local anesthesia, acetaminophen, ibuprofen, gabapentin, ketamine and lidocaine.

Mobility post-surgery – When a patient wakes up in the recovery room, they are encouraged and assisted in early mobility in and around the bed. This mobility helps to speed up the recovery process, getting them back home and back to their lives faster.

“Since the early 90s, Geisinger has been pioneering patient-centric programs that revolutionize care design and management, paving the way for the industry in the move to value,” said Jaewon Ryu, MD, JD, Geisinger’s interim president and chief executive officer.

“ProvenRecovery is a natural evolution of these efforts, building on the successes of our ProvenCare program. By getting patients healthier and out of the hospital sooner, not only are we improving lives, we’re also reducing overall costs of care.”

ProvenRecovery is the latest innovation from Geisinger, building on the organization’s work in genomic medicine with the MyCode® Community Health Initiative research, and addressing food insecurity and diabetes through its Fresh Food Farmacy®.

Award winning Schoen Clinic attends Arab Health 2019 to showcase brand new Harley Street hospital http://www.hhmglobal.com/knowledge-bank/news/award-winning-schoen-clinic-attends-arab-health-2019-to-showcase-brand-new-harley-street-hospital Tue, 20 Nov 2018 08:47:39 +0000 http://www.hhmglobal.com/uncategorized/award-winning-schoen-clinic-attends-arab-health-2019-to-showcase-brand-new-harley-street-hospital Schoen Clinic London, located within the Harley Street Medical Area, will provide patients with access to rapid assessment, expert diagnosis and world-class treatment outcomes from leading orthopaedic surgeons, as well as the Group’s award-winning approach to quality outcome measurement.

Schoen Clinic – the largest family-run hospital group in Germany – will be at Arab Health 2019 to showcase its first purpose-built hospital outside of its home country.

Schoen Clinic London, located within the Harley Street Medical Area, will provide patients with access to rapid assessment, expert diagnosis and world-class treatment outcomes from leading orthopaedic surgeons, as well as the Group’s award-winning approach to quality outcome measurement.

The purpose-built hospital contains 10 consultation rooms, two minor treatment rooms, a physiotherapy department with gym and a fully-equipped imaging suite with MRI, CT and digital x-ray.

For inpatients, the seven-floor building also includes three laminar flow theatres, eight bespoke day beds and 39 ensuite inpatient bedrooms, including a VIP suite with roof terrace and private access, as well as 24/7 access to an onsite Resident Consultant Intensivist.

Every effort has been made to ensure that patients will experience a healing environment at Schoen Clinic London. This has been created through the use of natural light in all rooms, wooden furnishings and decorative privacy screens, featuring scenes such as forest sunlight or blue skies.

Christopher Schön, chief operating officer of Schoen Clinic Group, said, “The opening of Schoen Clinic London is a hugely important milestone and we are extremely excited to showcase our state-of-the-art facility at Arab Health.”

“Our facilities are combined with world-leading healthcare professionals and we are personally committed to constant improvement. This means patients from across the Middle East visiting us in London will be receiving the best orthopaedic care available, anywhere.”

Schoen Clinic is located within the Harley Street Medical Area, London – an area famed for its medical excellence in treating complex and life-threatening conditions. The area, managed by long-term landlord The Howard de Walden Estate, brings together a community of world-renowned medical professionals.

The Arab Health Exhibition & Congress is taking place from 28-31 January 2019 at the Dubai Convention and Exhibition Centre. Throughout the exhibition Schoen Clinic team will be located on the Harley Street Medical Area Stand on the UK Pavilion (hall 7 stand E30).

More info about Harley Street Medical Area
The Howard de Walden Estate is the guardian of the Harley Street Medical Area and has been supporting and nurturing medical excellence in this historic part of London for 200 years. The Harley Street Medical Area is a collective of hospitals, clinics and specialists who deliver outstanding patient care through pioneering treatments and cutting-edge technologies. The Harley Street Medical Area has over 5000 medical specialists and over 250 clinics working within 92 acres of Marylebone, central London. The Harley Street Medical Area brings together a community of medical professionals who provide access to the best medical treatments and services in the world and are at the forefront of advancing global medical practices in the City of London.

Cleveland Clinic Genetic Analysis Links Obesity with Diabetes, Coronary Artery Disease http://www.hhmglobal.com/industry-updates/press-releases/cleveland-clinic-genetic-analysis-links-obesity-with-diabetes-coronary-artery-disease Mon, 19 Nov 2018 08:48:49 +0000 http://www.hhmglobal.com/uncategorized/cleveland-clinic-genetic-analysis-links-obesity-with-diabetes-coronary-artery-disease A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published today in the Journal of the American Medical Association Network Open.

Coronary artery disease -and complications that arise from it, such as heart attacks and heart failure- is the leading cause of the death in the United States and across the world. While other factors such as high cholesterol have been tied to coronary artery disease, the association between obesity and cardiovascular disease has not been clearly established.

For this study, researchers performed a meta-analysis of five studies with more than 880,000 participants. Researchers examined participants’ genetic variations using a method called Mendelian randomization, which offers insight into the relationships between health risks and health outcomes. By relying on genetic data, this method removes confounding, or outside, variables that can extraneously influence outcomes, such as smoking, high blood pressure, or elevated cholesterol. Mendelian randomization cannot prove causality, but it can be suggestive of a causal association – as was the case in this study.

“This study is important because we can conclude that it is not solely factors like high blood pressure, high cholesterol or lack of exercise that tend to come with obesity that are harmful – the excess fat itself is harmful,” said Haitham Ahmed, M.D., the senior author of the study and a preventive cardiologist at Cleveland Clinic. “Patients may think their cardiovascular risk is mitigated if their other risk factors are normal or being treated, but this study suggests you cannot ignore the extra weight. Physicians should take heed and make sure they are counseling their patients about weight loss in a comprehensive and collaborative manner.”

The study showed that each five-point rise in BMI, for example from a BMI of 25 to a BMI of 30, increased the odds of Type 2 diabetes by 67 percent and coronary artery disease by 20 percent. In light of the Mendelian randomization, these increases are thought to be independent of traditional risk factors. This means the risks hold true even if the patient has, for example, normal cholesterol, blood pressure and blood sugar. Three of the studies analyzed also included stroke as a clinical outcome, but the researchers did not find a significant association between obesity and all-cause stroke.

“It is very important to recognize that while lifestyle factors certainly contribute to obesity, obesity is not simply a lifestyle choice. It is a disease, and there is large genetic influence on your weight,” Dr. Ahmed said. “Our data show that nearly 100 genetic variations influence the development of obesity and subsequently increase your risk of heart disease.”

According to the CDC, 39.8 percent of U.S. adults are obese. Meanwhile, World Health Organization reports 13 percent of the world’s adult population is obese and that the prevalence of obesity has tripled between 1975 and 2016. Obesity rates, along with rates of cardiovascular disease and diabetes, are expected to continue to rise, if current trends continue.

Cordis Launches MYNX CONTROL Vascular Closure Device http://www.hhmglobal.com/industry-updates/press-releases/cordis-launches-mynx-control-vascular-closure-device Mon, 19 Nov 2018 08:28:40 +0000 http://www.hhmglobal.com/uncategorized/cordis-launches-mynx-control-vascular-closure-device Cordis, a Cardinal Health company, announced the U.S. launch of MYNX CONTROL™ Vascular Closure Device (VCD). MYNX CONTROL™ VCD integrates active extravascular sealing and resorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7F femoral arterial access sites. Vascular closure devices reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional procedures.1

MYNX CONTROL™ VCD features a next-generation deployment system that is designed for predictable deployment and ease of use. It will be available in 5F as well as 6/7F sizes. Highlights of this new system include:

  • sheath catch that is compatible with the procedural sheath
  • tension indicator that provides visual confirmation of device position for proper sealant deployment
  • Cordis Launches MYNX CONTROL Vascular Closure Device ergonomic handle with a 2-button deployment design to simplify procedural steps

Leveraging the proven MYNXGRIP® VCD technology, which has been used in over two million interventional cases worldwide, the MYNX CONTROL™ VCD utilizes a dual-mode active sealing mechanism. This allows the sealant to interlock with the contours of the arterial wall, expanding to fill the tissue tract and create a matrix structure for clot formation. With all closure components resorbing within 30 days, nothing is left behind. The MYNX® VCD technology has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort.1-6

“The notion of secure extravascular closure with nothing left behind is very appealing for a number of reasons,” said Ali Almedhychy, MD, global medical director at Cordis. “In addition to the clinical benefits of undisrupted flow in the artery, MYNX CONTROL™ VCD minimizes technique-related issues and emphasizes simplicity and reproducibility.”

“MYNX CONTROL™ VCD reinforces Cordis leadership in global vascular closure innovation,” commented Patrick Holt, president at Cordis. “By adding new access, diagnostic, interventional and closure products to our portfolio, we continue to make significant patient-centric contributions to the delivery of healthcare.”

As a global leader in the treatment of cardiovascular disease, Cordis continues to grow its product portfolio, including via recent strategic alliances, bringing customers the EluNIR® Drug-Eluting Stent (DES), TRYTON Side Branch Stent, and MOZEC™ PTCA Balloon Dilatation Catheters.

Demand dictates that ABHI doubles its US ‘Innovation Hub’ http://www.hhmglobal.com/knowledge-bank/news/demand-dictates-that-abhi-doubles-its-us-innovation-hub Mon, 19 Nov 2018 07:16:22 +0000 http://www.hhmglobal.com/uncategorized/demand-dictates-that-abhi-doubles-its-us-innovation-hub The Association of British HealthTech Industries (ABHI) has taken another important step in supporting UK HealthTech companies do business in the US by doubling the capacity of their Innovation Hub. Following the success of the first cohort, another eight companies have joined.

The Hub is a unique partnership between ABHI, the UK’s health technology trade association, and the Dell Medical School at The University of Texas in Austin. Companies include: Firstkind Medical, Rightangled Diagnostics, Owen Mumford, Directed Systems, Virti, DCC Vital and Aleisi Surgical.

Each business will be able to work closely with leaders from The University of Texas, accessing Dell Med’s full range of facilities, innovation teams and faculty, whilst being supported by ABHI’s network of connections across Texas’ four major cities. They can also take advantage of ABHI’s highly developed HealthTech network, including investors, hospital systems, chambers of commerce and key business groups.

Another unique feature is access to a team of senior mentors who are on-hand to offer bespoke support, as well as ABHI’s dedicated year-round support and introductions across the US.

Located within Austin’s Health District, the Hub is a key base for UK companies as it is one of the city’s largest and most anticipated development projects. The district physically links Dell Medical School to its key partners, Seton Healthcare Family and Central Health and includes 600,000 square feet of space dedicated to innovative education, care and research.

The Innovation Hub is part of the ABHI’s broader US Accelerator programme which also includes two tailored trade missions to key US HealthTech hubs, developed to forge and develop partnerships with leading clinical communities.

Jackie Fielding, Regional Vice President for Medtronic and Vice Chair of the ABHI Board of Directors said: “We are deeply supportive of the work ABHI is doing to assist UK companies with their export strategies, and the ABHI Innovation Hub is a prime opportunity for businesses to develop operations stateside. On behalf of the ABHI Board, I am delighted with how well the US Accelerator Programme is going and we are proud to be developing these two-way trading partnerships.”

Ruben Rathnasingham, Assistant Dean for Health, Product Innovation at Dell Medical School added: “Since the launch of the ABHI Innovation Hub at Dell Med, we have met with, and learned from, numerous small and large UK businesses, academic medical centers and health systems. We have helped several UK-based businesses connect with key US market leaders and are also in active partnership discussions with UK-based start-ups who now have a presence in Austin. ABHI’s International Program, that supports US-based companies enter and explore the UK market, has been a further value-driver for our partnership.”

About ABHI
ABHI is the UK’s leading health technology trade association. With over 275 members, ABHI supports the health technology community to provide products and services that help people live healthier lives. Our work is focused on showing the value of HealthTech and encouraging a healthy environment for economic growth. We help companies understand HealthTech regulation and our work is underpinned by our Code of Business Practice, which all Members adhere to.

About the ABHI Innovation Hub
Positioned within one of city’s largest and most anticipated development projects, the Austin Health District, the Hub is located on the Dell Medical School campus. With a focus on delivering population health and value-based care, Austin’s economy is technology-led, and the Dell Medical School are focussed on delivering outcomes through this methodology. Companies included in the first phase of the hub include Lumeon, Forte Medical, Timesco, P3 Medical, Deltex Medical, Endomag and Deontics, who all have long-term plans to up-scale their US activities.

Merck Foundation announces the winners for their “Merck Diabetes Award” to mark “World Diabetes Day 2018” http://www.hhmglobal.com/industry-updates/press-releases/merck-foundation-announces-the-winners-for-their-merck-diabetes-award-to-mark-world-diabetes-day-2018 Thu, 15 Nov 2018 11:16:05 +0000 http://www.hhmglobal.com/uncategorized/merck-foundation-announces-the-winners-for-their-merck-diabetes-award-to-mark-world-diabetes-day-2018 Merck Foundation marked the “World Diabetes Day” themed ‘The Family and Diabetes’ on 14th November 2018. Merck Foundation to provide One Year on-line Post-graduate Diploma in Diabetes Management from UK to the winners of the Merck Diabetes Award 2017.

Merck Foundation (Merck-Foundation.com), the philanthropic arm of Merck KGaA Germany marked ‘World Diabetes Day 2018’ by announcing the winners of Merck Diabetes Awards 2017 and call for application for Merck Diabetes Award 2018.

“Merck Foundation launched ‘Merck Diabetes Award’ in 2016 in more than 30 African and Asian universities in partnership with health ministries. The aim is to build a platform of diabetes experts across the globe. This year we discussed the concept of involving our partners from First ladies and ministries of health in 10 African countries in selecting the winners and the candidates for this valuable diploma so that they can establish diabetes clinics across the counties in each country, this will be a strong milestone of improving access to quality and equitable diabetes care, not only in the capital but nationwide” emphasizes Dr. Rasha Kelej, CEO of Merck Foundation.

Winners of the Merck Diabetes Award 2017 were announced this year. The award attracted over 500 concept submission applications from universities in Africa and Asia. The winners from each university have been provided with an opportunity to study for a one-year online Post Graduate Diabetes Diploma from the South Wales University, United Kingdom.

Merck Foundation will also provide an opportunity to winners from French speaking countries to enroll for a three month foundation Course on Diabetes in French, accredited by the Royal College of General Practitioners, UK.

Merck Foundation also announced the call for application for the medical students to apply for the “Merck Diabetes Award” 2018-19 with the theme “Every Day is a Diabetes Day.” Medical graduates across African and Asian medical universities have been asked to submit a concept paper on how to improve diabetes early detection and prevention in their countries and how to encourage their society, scientific community, local authorities, media and relevant stakeholders to think and act on diabetes every day. The deadline for the submission of the entries is 31st January 2019.

“Merck Diabetes Award marks another milestone of our commitment to working with governments, academia and relevant stakeholders in building healthcare capacity with a focus on non-communicable diseases in developing countries,” added Dr. Rasha Kelej.

Dr. Goufon kuete Herve from Cameroon, an award winner from Merck Diabetes Award 2017 says, “As a physician working in a rural setting where most patients referred to tertiary hospitals, die on their way due to diabetic complications, this program will enable me to properly manage the patients, thereby reducing the morbidity and mortality associated with this health burden.”

Fu Mei Sian from Malaysia, another award winner said “I am delighted to be the winner of this award, as it this will enable me to improve my knowledge and experience and provide my expertise to the people of my country”

Meet some of the winners of “Merck Diabetes Awards 2017”, the Future Diabetes Experts, stay tuned for the 2018 winners:

  • Dr.Nishmita.R, Bangalore Medical College and Research Institute, India
  • Serge Yannick OUEDRAOGO, University Ouaga, Burkina Faso
  • Mlondolozi Malloy, Walter Sisulu University, South Africa
  • Misago Nadine, University of Burundi, Burundi
  • Menaka Ponnamperuma, Postgraduate Institute of Medicine, Sri Lanka
  • Victor Ekem, University of Ghana Medical School, Ghana
  • Dr. Okello Samuel Moses, Makerere University College of Health Sciences, Uganda
  • Dr. Goufon kuete Herve, Graduated from the University of Buea, Cameroon
  • Amulo Anyoti, Kilimanjaro Christian College, Tanzania
  • Dellaneira Setjiadi, Padjadjaran University, Indonesia
  • Hassane Adamou Nasser, Alexandria University, Niger
  • NDAGIWENIMANA Sylvain, University of Rwanda, Rwanda
  • Judy G. Ayiega, Kenyatta University, Kenya
  • Fu Mei Sian, University Malaya, Malaysia
  • Dr. Adetola Rachael ADEYEYE, University of Ilorin, Nigeria
  • Muzzammil Ismail, University of Cape Town, South Africa
  • Mohamad Rahman Suhendri, Islamic University of Indonesia, Indonesia
  • Papy Baosolange, University of Kivu, Democratic Republic of Congo
  • Ashleigh Sent, University of Pretoria, South Africa
  • Bersabeh Mekasha Kassaye, Addis Ababa University, Ethiopia
  • David CHEA, University of Health and Sciences, Cambodia
  • Mohamed A. Omar, University of Nairobi, Kenya
  • Arifa Siddiqua, Dhaka University, Bangladesh
  • Shingirai Muzondiwa, University of Botswana, Botswana
  • Peva F. Gbagornah, A.M. Dogliotti College of Medicine, University of Liberia, Liberia

Distributed by APO Group on behalf of Merck Foundation.

About Merck Foundation:
The Merck Foundation (Merck-Foundation.com), established in 2017, is the philanthropic arm of Merck KGaA Germany, aims to improve the health and wellbeing of people and advance their lives through science and technology. Our efforts are primarily focused on improving access to innovative healthcare solutions in underserved communities, building healthcare and scientific research capacity and empowering people in STEM (Science, Technology, Engineering, and Mathematics) with a special focus on women and youth. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website. Please go to Merck-Foundation.com to read more and/or register online to interact and exchange experience with our registered members.

Abstract submission for the 43rd World Hospital Congress now open http://www.hhmglobal.com/knowledge-bank/news/abstract-submission-for-the-43rd-world-hospital-congress-now-open Thu, 15 Nov 2018 09:20:47 +0000 http://www.hhmglobal.com/uncategorized/abstract-submission-for-the-43rd-world-hospital-congress-now-open The 43rd World Hospital Congress of the International Hospital Federation opens its call for paper presentations and posters, inviting professionals from hospitals and health service delivery organizations to submit their abstracts.

The International Hospital Federation and the Ministry of Health of the Sultanate of Oman, organizers of the 43rd World Hospital Congress, are inviting health leaders and professionals to submit abstracts for an opportunity to showcase their work at the next congress being held in Muscat, Oman on 7-9 November 2019.

The IHF World Hospital Congress is a unique global forum that brings together leaders of national and international hospital and healthcare organizations. Through this event multi-disciplinary exchange of knowledge, expertise and experiences are facilitated, together with dialogue on best practices in leadership in hospital and healthcare management and delivery of services.

The 2019 Congress will tackle the overarching theme “People at the heart of health services in peace and crisis”.

Those interested to present their work to the international healthcare community in a session or as a poster can submit an abstract online against the following sub-themes:

  1. Resilient health services
  2. Innovation for health impact
  3. Health investment for prosperity

Chosen abstracts will also be considered for publication in the IHF Journal and present in an IHF Webinar.

Deadline of abstracts is on 15 February 2019. For more information on the sub-themes, submission process, general criteria and terms and conditions for presenters, click here.

If you have any questions, please visit www.worldhospitalcongress.org.

Estrogen Replacement Accounts for Over 80 Percentage of Hormone Replacement Therapy Market Revenues http://www.hhmglobal.com/industry-updates/press-releases/estrogen-replacement-accounts-for-over-80-percentage-of-hormone-replacement-therapy-market-revenues Thu, 15 Nov 2018 09:04:39 +0000 http://www.hhmglobal.com/uncategorized/estrogen-replacement-accounts-for-over-80-percentage-of-hormone-replacement-therapy-market-revenues The hormone replacement therapy market is foreseen to expand at a significant pace with sales of products crossing US$ 12,000 Mn by 2019 end. Rising incidences of osteoporosis fractures coupled with growing menopause rates among women have remained instrumental in driving the demand. Fact.MR envisages that the demand is projected to expand at a CAGR of 6% in terms of value throughout the period of forecast, 2018-2028.

Disorders associated with hormonal imbalance continue to influence the use of hormone replacement therapy worldwide. The demand is further pushed with macroeconomic aspects such as growing geriatric population and significant increase in healthcare expenditure worldwide. Growing age directly impacts secretion of hormones such as progesterone and estrogen in women, which is expected to trigger the use of estrogen hormone replacement therapy.

Expanding range of menopausal window (45-55 years) coupled with growing number of postmenopausal patients are few of the key factors influencing the growth of the market. According to the report, the demand for estrogen hormone replacement therapy is expected to grow on the back of growing menopausal rate worldwide. The sales of estrogen hormone replacement therapy are likely to surpass US$ 18,000 Mn by 2028, higher than those of other products including thyroid and growth hormone related hormone replacement therapy products, says the study.

Sales of hormone replacement therapy products through hospital pharmacies and retail pharmacies are likely to be on an upswing with developers relying on these channels than online selling. Retail pharmacies are expected to remain an attractive distribution channel for the products, with sales accounting for a larger revenue share of the overall hormone replacement therapy market. The sales of hormone replacement therapy through clinics are projected to grow at a steady during the 2018-2028 timeline.

The market is expected to remain influenced by increasing government support apropos to women’s health. Governments and non-profit organizations of various countries are spreading awareness regarding hormone replacement therapy along with providing free treatments to lower and middle class people. Regulatory authorities such as FDA are also contributing to the cause of supporting women’s health by launching initiatives such as Take Time To Care (TTTC) programs. This aspect is likely to support the growth of the market in the coming years.

Sales are likely to remain concentrated among developed countries of North America and Europe. Tug-of-war between North America and Europe apropos to demand for hormone replacement therapy has been witnessed since the past couple of years, with the latter gaining tempo over the former, says the study.

Stakeholders in the hormone replacement therapy can find attractive opportunities in developed countries in North America, particularly the United States. According to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause every day, reaching a count of over 2 million annually. This has translated into significant adoption in the country. The demand in the US is also accompanied by higher GDP per capita, triggering high healthcare expenditure.

The study also foresees that the hormone replacement therapy market in Asia Pacific excluding Japan (APEJ) region is poised to expand at a relatively higher pace as compared to other regions. According to the study, the APEJ hormone replacement therapy market is projected to expand at a stellar pace of 7.2% during the assessment period. This growth can be attributed to increasing population coupled with higher life expectancy in emerging economies such as India and China. Against this backdrop, stakeholders in hormone replacement therapy market can expect optimistic growth in the region in the years to follow, leveraging its lucrativeness from an investment standpoint.

The insights presented here are from a research study on Hormone Replacement Therapy by Fact.MR

International offering for Single Use Surgical’s Pulse Lavage and Spackman Cannula http://www.hhmglobal.com/knowledge-bank/news/international-offering-for-single-use-surgicals-pulse-lavage-and-spackman-cannula Thu, 15 Nov 2018 06:17:38 +0000 http://www.hhmglobal.com/uncategorized/international-offering-for-single-use-surgicals-pulse-lavage-and-spackman-cannula Surgical Use Surgical – a UK surgical instrument specialist that offers ‘gold standard’ disposable solutions – will be at MEDICA 2018 (12 – 15th November) to raise awareness of their Pulse Lavage kit and the Spackman Cannula.

Based in Cardiff, the disposable surgical instrument specialist prides itself on identifying difficult-to-clean surgical equipment and offering high quality, alternative single use solutions.

The Pulse Lavage kit features a built-in battery pack, which can be easily disconnected for safe disposal, offering a superior alternative to traditional “hanging” packs. The device includes a controlled pulsed irrigation and suction feature and comes with two additional tips designed specifically for the hip and knee, ideal for a range of applications including Orthopaedic revisions, total joint procedures, trauma and wound care.

Single Use Surgical solutions for Gynaecology and fertility, include the Spackman Cannula. Its ergonomic design featuring a unique self-locking clamp enables convenient single-handed use, whilst ensuring an excellent seal on the cervix thanks to the functionality of the moving acorn.The range of solutions for both Orthopaedics and Gynaecology help to combat concerns over cleanliness and the cost and inconvenience of reprocessing a reusable equivalent.

Established in 2001, Surgical Use Surgical was formed as a direct response to UK hospitals’ concerns over the cleaning practices involving fine lumen instruments. The company’s ethos is simple – to produce instruments that are sterile, efficient and manufactured to the highest standards, all carefully designed to put patients first and reduce the risk of cross contamination.

16256 - Pulse_Lavage.pngToday, Surgical Use Surgical manufacture the world’s largest selection of single use suction devices with its extensive range spanning into many specialities including ENT, Head and Neck, Gynaecology, Laparoscopy, General and Vascular surgery.

The suctions capture the same look, feel and functionality as the reusable equivalent and have been well received globally. The company continues to grow rapidly in many markets around the world and will be at MEDICA 2018 to source new global distributor partners.

Export Manager, Michael Denver, said: “We are always looking to expand our partner database and are keen to speak to interested partners at MEDICA 2018. We are fully committed to delivering high quality products, reliability and consist customer service with dedicated product support that global partners, both new and old, require to serve and nurture their markets.”